Provided by Tiger Trade Technology Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

11.93
+0.05000.42%
Pre-market: 12.330.4025+3.37%05:34 EDT
Volume:2.70M
Turnover:31.91M
Market Cap:1.79B
PE:-2.66
High:12.12
Open:11.83
Low:11.46
Close:11.88
52wk High:18.57
52wk Low:7.48
Shares:150.42M
Float Shares:117.99M
Volume Ratio:1.33
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4800
EPS(LYR):-6.8648
ROE:-799.46%
ROA:-71.98%
PB:146.82
PE(LYR):-1.74

Loading ...

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

THOMSON REUTERS
·
Aug 26

Biohaven - SK Biopharmaceuticals to Pay up to $795 Mln Plus Tiered U.S. Royalties to Biohaven

THOMSON REUTERS
·
Aug 26

Biohaven - to Receive $400 Mln Cash, Including $350 Mln at Closing and $50 Mln in 2027

THOMSON REUTERS
·
Aug 26

Biohaven - Eligible for $150 Mln in Development and Regulatory Milestones Plus Global Royalties

THOMSON REUTERS
·
Aug 26

Biohaven Receives Favorable Ruling in the Trade Secret Misappropriation Lawsuit

MT Newswires Live
·
Aug 26

Biohaven - Federal Court Confirms Ra Capital and Avilar Therapeutics "Misappropriated" Yale Trade Secret

THOMSON REUTERS
·
Aug 26

Biohaven - U.S. District Court Awards $4 Mln to Biohaven and Yale in Trade Secret Case

THOMSON REUTERS
·
Aug 26

Biohaven Files Form 3 Initial Beneficial Ownership Statement for Director John Yetimoglu

Reuters
·
Aug 15

Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says

MT Newswires Live
·
Aug 11

RBC Adjusts Price Target on Biohaven to $23 From $22, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 11

Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Biohaven Ltd. (BHVN)

TIPRANKS
·
Aug 11

Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate

Benzinga Earnings
·
Aug 11

Biohaven Ltd. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Biohaven Q2 Adjusted Loss Narrows

MT Newswires Live
·
Aug 11

Biohaven Q2 Net Loss Narrows on Lower R&D Spend

Reuters
·
Aug 11

Biohaven Q2 FY26 Net Loss Narrows 30.7% to $137.31 Million; R&D Expenses Fall 45.34% to $100.81 Million

Reuters
·
Aug 11

Biohaven Q2 Basic EPS USD -0.91

THOMSON REUTERS
·
Aug 11

Biohaven Appoints John Yetimoglu to Board

Reuters
·
Aug 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 31